학술논문

Systemic sclerosis associated interstitial lung disease: a conceptual framework for subclinical, clinical and progressive disease.
Document Type
Article
Source
Rheumatology. May2023, Vol. 62 Issue 5, p1877-1886. 10p.
Subject
*DISEASE progression
*CONSENSUS (Social sciences)
*CONFIDENCE intervals
*SYSTEMIC scleroderma
*INTERSTITIAL lung diseases
*CONCEPTUAL structures
*SEVERITY of illness index
*DESCRIPTIVE statistics
*CHI-squared test
*RESEARCH funding
*EVALUATION
Language
ISSN
1462-0324
Abstract
Objectives To establish a framework by which experts define disease subsets in systemic sclerosis associated interstitial lung disease (SSc-ILD). Methods A conceptual framework for subclinical, clinical and progressive ILD was provided to 83 experts, asking them to use the framework and classify actual SSc-ILD patients. Each patient profile was designed to be classified by at least four experts in terms of severity and risk of progression at baseline; progression was based on 1-year follow-up data. A consensus was reached if ≥75% of experts agreed. Experts provided information on which items were important in determining classification. Results Forty-four experts (53%) completed the survey. Consensus was achieved on the dimensions of severity (75%, 60 of 80 profiles), risk of progression (71%, 57 of 80 profiles) and progressive ILD (60%, 24 of 40 profiles). For profiles achieving consensus, most were classified as clinical ILD (92%), low risk (54%) and stable (71%). Severity and disease progression overlapped in terms of framework items that were most influential in classifying patients (forced vital capacity, extent of lung involvement on high resolution chest CT [HRCT]); risk of progression was influenced primarily by disease duration. Conclusions Using our proposed conceptual framework, international experts were able to achieve a consensus on classifying SSc-ILD patients along the dimensions of disease severity, risk of progression and progression over time. Experts rely on similar items when classifying disease severity and progression: a combination of spirometry and gas exchange and quantitative HRCT. [ABSTRACT FROM AUTHOR]